MedTrace Logo

The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)

NCT00485394 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2008-04-02

No results posted yet for this study

Summary

The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

OT-551

OT-551 0.3% ophthalmic solution, 2 drops 4 times daily

DRUG

OT-551

OT-551 0.45% ophthalmic solution, 2 drops 4 times daily

DRUG

vehicle placebo

OT-551 0% ophthalmic solution, 2 drops 4 times daily

Sponsors & Collaborators

  • Othera Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00485394 on ClinicalTrials.gov